A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan

Exclusion Criteria

• •Participants with diabetes other than T2DM
• •H2S app/ BGM is not appropriate for the participant or use of device is otherwise contraindicated (in the opinion of the investigators)
• •Participants with hypoglycemia unawareness or with severe hypoglycemia within the past 90 days prior to the screening visit and until Day 1
• •Hospitalization (for any reason) in the past 30 days prior to the screening visit and until Day 1
• •Participants with severe conditions/concomitant diseases precluding their safety or ability to participate in this study, as judged by the investigators - Participants are not on stable dose of glucose lowering therapy including OADs, glucagon-like peptide-1 (GLP-1) receptor agonists, or basal insulin therapy within the past 12 weeks prior to the screening visit and until Day 1 per investigator's discretion
• •Participants using mealtime insulin for more than 10 days in the last 90 days before the screening visit and until Day 1
• •Participants who used H2S app within 1 month prior to the screening visit and until Day 1 randomization
• •Participants who have taken other investigational drugs within 90 days or 5 half-lives prior to screening or randomization, whichever is longer
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.